drugset / Trial / NCT01449162
Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.
Timeline
- Start
- 2011-01
- Primary completion
- 2019-11
- Completion
- 2019-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masitinib | Small molecule | 6 mg/kg | Oral |